OBJECTIVE: Given the association between risk of @entity306 and @entity1 born to @entity28 @entity1 , the study aim was to estimate whether @entity28 is associated with reduced effectiveness of conventional antenatal @entity2399 dosing for the prevention of @entity306 and @entity204 . STUDY DESIGN: This is a secondary cohort analysis of a multicenter randomized clinical trial completed by the Maternal-Fetal Medicine Units Network. @entity1 were included in the original trial if deemed high risk for @entity3152 in the subsequent 24 hours. The present study included singleton, nonanomalous fetuses that were randomized to and received @entity2399 with complete data available. Outcomes between @entity28 (body mass index >= 30 kg/m(2)) and nonobese @entity1 were compared. A secondary analysis of outcomes between morbidly @entity28 (body mass index >= 40 kg/m(2)) and nonmorbidly @entity28 @entity1 was performed. The primary outcome was a composite of @entity306 or perinatal @entity204 before 15 months corrected age. Secondary outcomes included moderate to severe @entity306 or @entity204 , any @entity306 , moderate to severe @entity306 , and @entity204 . A logistic regression analysis was used to estimate the odds ratio of each outcome. Based on sample size, exposure rate ( @entity28 ) and an outcome rate of 10%, assuming an 80% power and a 0.05 alpha error, this study had sufficient power to detect a 2-fold increase in the primary outcome. RESULTS: Of 1188 @entity1 randomized to receive @entity2399 , 806 were included in this analysis. After adjusting for gestational age at delivery, @entity28 was not associated with an increased risk of @entity306 or @entity204 in @entity1 born to @entity1 who received @entity2399 . @entity1 with morbid @entity28 had higher rates of the primary outcome and @entity306 in an unadjusted analysis but did not have increased risks after adjusting for gestational age at delivery. In analyses stratified on gestational age, morbidly @entity28 @entity1 who delivered after 28 weeks had increased risks of @entity1 with @entity306 or @entity204 and @entity306 , although case numbers were small. CONCLUSION: Among @entity1 receiving antenatal neuroprotective @entity2399 , @entity28 is not associated with an increased risk of having a @entity1 with @entity306 or @entity204 .

Maternal XXXX and neuroprotective @entity2399 .

@entity1 :: ('9606', 'Species') :: ['women', 'children', 'Women', 'child'] @entity3152 :: ('MESH:D007752', 'Disease') :: ['preterm delivery'] @entity2399 :: ('MESH:D008278', 'Chemical') :: ['magnesium sulfate'] @entity28 :: ('MESH:D009765', 'Disease') :: ['maternal obesity', 'obese', 'obesity'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death'] @entity306 :: ('MESH:D002547', 'Disease') :: ['cerebral palsy']
@entity28 :: (MESH:D009765,Disease) :: ['obesity']
